Back in February 2014, we wrote an article for Seeking-Alpha reviewing the recently published Phase 1 data on Neuralstem's (NYSEMKT:CUR) NSI-566 for the treatment of Amyotrophic Lateral Sclerosis ("ALS"). This article is now exclusive to PRO subscribers, but we can point investors to the full peer-reviewed paper published in the Annals of Neurology (Feldman et al, 2014) for a comprehensive review of the Phase 1 study. Below we summarize some of the conclusions from that paper, and then point to significant anecdotal evidence that the current Phase 2 study is not only proceeding well, but succeeding in its primary goal of demonstrating safety and efficacy of NSI-566 for the treatment of ALS.
…Quick Review of ALS,
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|